April 23rd 2025, 9:00pm
By Alex Biese
Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.
April 23rd 2025, 8:00pm
By Dr. Douglas Reznick
Dr. Douglas Reznick shares advice for patients with lung or head and neck cancer who may feel overwhelmed by their diagnosis.
April 23rd 2025, 7:00pm
By Joy Anderson
A push for answers led to a rare blood disorder diagnosis after Joy’s symptoms were initially dismissed.
April 23rd 2025, 5:00pm
By Linda Cohen
As spring arrives, I embrace the season’s renewal, reflecting on my journey with cancer and the freedom I’ll feel when I stop my treatment. Life is a gift.
April 23rd 2025, 4:00pm
In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free survival results.
April 23rd 2025, 2:59pm
By Ryan Scott
The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse intrinsic pontine glioma.
April 23rd 2025, 1:00pm
By Spencer Feldman
April 22nd 2025, 9:00pm
By Erin Longstreth, M.S.N., RN, OCN, NEA-BC
April 22nd 2025, 8:00pm
By Dr. Matthew Matasar
April 22nd 2025, 7:00pm
By Anne M. Reb
An expert sat down to discuss the emotional and physical barriers patients may face when seeking support for fear of cancer progression.
April 22nd 2025, 4:54pm
By Karen Cohn
It’s spring, a time for new beginnings following a cancer diagnosis; however, I have an ongoing issue that I can’t dismiss.
April 22nd 2025, 4:14pm
The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.
April 22nd 2025, 3:21pm
The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence risk and treatment decisions.
April 22nd 2025, 1:00pm
Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder cancer, based on the NIAGARA trial.
April 21st 2025, 9:00pm
By Carey Ramirez, ANP-C, ACHPN
“Don’t aspire to make a living. Let’s aspire to make a difference in the Mandarin/Cantonese-speaking community.”
A Cancer Survivor Rethinks Cancer Ghosting
A Story of Staying Active After a Lung Cancer Diagnosis
Experts Discuss New Advances in Bladder Cancer Following ESMO 2025
What I Learned About Previvorship and Representation in Social Media